** Shares of India's Aster DM Healthcare ATRD.NS rise as
much as 10.3% to hit a record high of 316.60 rupees
** HSBC Global Research keeps "buy" rating but raise its
target price to 330 rupees from 264 rupees
** Says strong revenue growth to continue, but new
hospitals' losses to impact margins
** Says should the sale of Aster's Gulf-based business
occur, it would boost the balance sheet
** Adds stock now appears to reflect some possibility of
restructuring, which brokerage believes will unlock value
** Trading vol at 8X their 30-day daily moving avg
** 9 of 10 brokerages rate the stock "buy" or higher and 1
"hold"; their median PT is 297.50 rupees - Refinitiv data
** ATRD up 24.17% this year, as of last close
(Reporting by Meenakshi Maidas in Bengaluru)
((meenakshi.maidas@thomsonreuters.com;))